Andros Pharmaceuticals Co.,Ltd
6917
Rank in Stocks
#22698
Andros Pharmaceuticals Co., Ltd. operates as a biopharmaceutical enterprise,... Andros Pharmaceuticals Co., Ltd. operates as a biopharmaceutical enterprise, concentrating on the advancement of novel drug delivery platform technologies. Its development pipeline features APC101, a metered-dose, quick-drying, film-forming spray undergoing Phase IIa clinical investigation for the management of pain linked to post-herpetic neuralgia. Also in development is APC201, an innovative topical anesthetic formulation currently in Phase I/II trials for Osteoarthritis treatment, alongside an siRNA (small interfering RNA) compound functioning as an antisense oligonucleotide and DNA candidate. In the preclinical phase, the company is advancing APC310 and APC501, both intended as anesthetics for intravenous catheter insertion and venipuncture. Another preclinical asset, APC401, is a specialized emulsified solution targeting post-surgical pain relief. Beyond its developmental programs, Andros Pharmaceuticals also provides LALP cream for dermal analgesic use, iMinos solution for treating Alopecia Androgenetica, and T4 endonuclease V. Established in 2008, the firm maintains its headquarters in Zhubei, Taiwan.
Share Price
$0.92063065
Last synced: 2026-11-10
Market Cap
$50.61M
Change (1 day)
-1.79%
Change (1 year)
35.55%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Andros Pharmaceuticals Co.,Ltd (6917)
Category
Healthcare
Operating Margin for Andros Pharmaceuticals Co.,Ltd (6917)
Operating Margin as of November 2026 TTM: -625.22%
According to Andros Pharmaceuticals Co.,Ltd's latest financial reports, its current operating margin (TTM) is -625.22%. At the end of 2025 the company had an operating margin of -1,363.30%.
Operating Margin history for Andros Pharmaceuticals Co.,Ltd from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -625.22% | -54.14% |
| 2025 | -1,363.30% | -96.91% |
| 2024 | -44,142.86% | 382.09% |
| 2023 | -9,156.52% | 285.28% |
| 2022 | -2,376.59% | 764.28% |
| 2021 | -274.98% | -78.83% |
| 2020 | -1,298.68% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.06% |
US
|
|
| -149.01% | -99.76% |
US
|
|
| 25.57% | -100.04% |
AU
|
|
| 31.23% | -100.05% |
BE
|
|
| 29.35% | -100.05% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Andros Pharmaceuticals Co.,Ltd's operating margin
What is Andros Pharmaceuticals Co.,Ltd's operating margin?
Andros Pharmaceuticals Co.,Ltd's operating margin is -625.22%, as of Nov 2026.
What was Andros Pharmaceuticals Co.,Ltd's operating margin in 2025?
In 2025, Andros Pharmaceuticals Co.,Ltd's operating margin was -1,363.30%, compared with -44,142.86% in 2024.
How has Andros Pharmaceuticals Co.,Ltd's operating margin changed since 2020?
From 2020 to 2025, Andros Pharmaceuticals Co.,Ltd's operating margin was highest in 2021 (-274.98%) and lowest in 2024 (-44,142.86%).
How does Andros Pharmaceuticals Co.,Ltd's operating margin compare with similar companies?
Andros Pharmaceuticals Co.,Ltd's operating margin (-625.22%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.